To sign up for our free research reports and newsletters, visit http://BeaconEquityResearch.com. For more information on our research programs, please contact: Jeff Bishop at editor@beaconequityresearch.com
Kayenta Kreations, Inc. (OTCBB: KKRI) Up 182.61% on Thursday
Detailed quote: http://beaconequityresearch.com/KKRI
December 06, 2007 - Geospatial Mapping Systems Agrees to Be Acquired by Kayenta Kreations
Geospatial Mapping Systems, Inc. a privately-held infrastructure technology company specializing in the mapping and management of underground pipeline systems has entered into a Letter of Intent to be acquired by Kayenta Kreations, Inc. (OTCBB: KKRI).
The proposed transaction is subject to certain conditions and will involve a change in stockholder control of the Company, change of management, change of corporate name, change of corporate headquarters and other significant matters. The proposed acquisition is expected to involve a 2.8 to 1 forward stock split of the currently outstanding shares of common stock of Kayenta. Subject to the conditions precedent the transaction is proposed to be completed on or about January 14th, 2008.
Skinvisible, Inc. (OTCBB: SKVI) Up 48.57% on Thursday
Detailed quote: http://beaconequityresearch.com/SKVI
December 06, 2007 - Skinvisible Signs Marketing Agreement for India
Skinvisible, Inc. (OTC Bulletin Board: SKVI) / (Website: http://www.skinvisible.com/), is pleased to announce that it has signed a marketing agreement with Avani International for India. This follows Skinvisible's recent announcement that it was granted a comprehensive patent in India for Skinvisible's proprietary polymer delivery system, Invisicare. Invisicare enhances the delivery of topical dermatology products on the skin.
The agreement with Avani is part of Skinvisible's continued strategy to quickly expand its reach around the globe. Avani will seek licenses in India for topical products Skinvisible has developed for the treatment of acne, fungal infections, atopic dermatitis and hand sanitizers. They will also facilitate clinical studies and manufacturing in India.
"It is important for Skinvisible to develop partnerships with companies such as Avani as they have established relationships with pharmaceutical and consumer goods companies in India. This helps us fast track our marketing efforts in the country and generate license fees and royalties quicker than marketing in India ourselves," said Mr. Terry Howlett, President and CEO of Skinvisible Inc.
"India and its expanding population of over 1 billion people offers tremendous market opportunities for Skinvisible and its Invisicare technology and products," said Ash Chawla, Chairman & CEO of Avani. "This agreement allows us to introduce Invisicare to Indian pharmaceutical manufacturers that we know need this technology."
S2C Global Systems (OTCBB: STWG) Up 42.86% on Thursday
Detailed quote: http://beaconequityresearch.com/STWG
December 06, 2007 - S2C Global Systems Creates New Water Brokering Division
S2C Global Systems (OTCBB:STWG) (http://www.s2cglobal.com/), designer and developer of the "S2C Aquaduct" commercial vending system that delivers pre-packaged, 5-gallon bottled water from the bottling plant to the consumer, has elected to establish a new division in its Canadian Subsidiary, S2C Global Systems, Inc. (British Columbia) brokering bottled water internationally. "Because of the International relationships developing in Africa and Europe we are in a position to broker sales of packaged water into those countries. It was a matter of matching up relationships we had in Canada with fulfillment needs in America, Africa and Europe," says S2C's CEO Rod Bartlett. "The missing component in taking on this business was someone that had the experience to develop the business on behalf of the company. We found this individual and went from there."
Andre Radermaker a twenty-year veteran of the water bottling industry has joined the S2C Global team as Vice President Procurement. Andre developed Natural Glacial Waters located on Vancouver Island which produces water for the Pacific Rim Market. Andre will be responsible for matching buyers and sellers of prepackaged water around the globe with the support of S2C Global. The first contracts are being secured to sell water overseas and are valued in excess of $17 Million dollars in gross sales. Andre will also draw upon his procurement background in equipment and packaging to source the same materials and services for S2C Global in the expansion of the S2C Aquaduct system.
SinoFresh HealthCare, Inc. (OTCBB: SFSH) Up 38.46% on Thursday
Detailed quote: http://beaconequityresearch.com/SFSH
December 06, 2007 - SinoFresh Non-Antibiotic Nasal Spray Initial Experiments Show Product Has a Complete Killing Activity of (MRSA) Methicillin Resistant Staphylococcus Aureus Strain MW2 Within 30 Seconds
SinoFresh HealthCare, Inc. (OTCBB: SFSH), developer of an over-the-counter nasal spray that kills bacteria and fungi, is pleased to announce up-coming human clinical trials to be conducted under the direction of the University of Chicago, School of Medicine. This study follows an earlier study conducted under the direction of Dr. Barry Kreisiwirth at the Public Health Research Institute at the International Center for Public Health where the following conclusions were reported:
"These initial killing experiments using SinoFresh Nasal Spray each show virtual contact killing of the well characterized community acquired Methicillin Resistant Staphylococcus Aureur strain MW2 had a complete killing activity within 30 seconds in the presence and absence of mucin and at a high bacterial concentration."
SinoFresh CEO, Charles Fust states: "We are pleased to see such profound interest emerging from the Medical Research community. Since the nasal passages are a known link in the infectious process of MRSA, I have been personally motivated over the years of SinoFresh Nasal & Sinus Care product development in determining if a new, non-antibiotic approach is feasible. The possibility of having a non-obtrusive, inexpensive preventative measure holds great potential. Based on pharmacologic mechanism of action of our compound, bacterial drug resistance is highly unlikely."
iVoice, Inc. (OTCBB: IVOI) Up 23.53% on Thursday
Detailed quote: http://beaconequityresearch.com/IVOI
December 06, 2007 - iVoice Receives Patent Award for ``Methodology for Talking Consumer Products with Voice Instructions via Wireless Technology''
iVoice, Inc. (OTC Bulletin Board: IVOI) - iVoice, Inc. (OTC Bulletin Board: IVOI), announced today it has received United States Patent, 7,305,344 for a patent "Methodology for Talking Consumer Products with Voice Instructions via Wireless Technology".
This invention enables users of new products to activate the speaking package of a new product, so there is no need to read instructions. For example, it provides for hands free, eyes free, instructions while assembling new products, such as bicycle, furniture, camera or other products.
To a person with low vision or a physical disability, talking instruction products can mean independence. Talking products offer independence to people with limited use of their hands or to people whose vision is limited. The result is greater satisfaction with their ability to control their own environment and less dependence on caregivers to attend to these common tasks.
"The grant of this patent is centrally important to iVoice, Inc. not only to preserve its technology but also to leverage offensively in the marketplace," said Mr. Mahoney. The patent award will make a significant milestone in product development for the iVoice technical staff. iVoice's commitment to innovation technology continues to help customers meet their client requirements. We believe that our intellectual property and our technology provide iVoice with a superior suite of application offerings.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN THIS DOCUMENT. ALL INFORMATION PROVIDED HERE IS MERELY INFORMATIONAL AND IS NOT INTENDED TO BE A RECOMMENDATION TO BUY OR SELL ANY SECURITY. YOU SHOULD CONSULT A LICENSED INVESTMENT PROFESSIONAL BEFORE MAKING ANY INVESTMENT DECISION. All material herein has been prepared by us based upon information believed to be reliable. The information contained herein is not guaranteed by us to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not always approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. We are not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed or mentioned herein. Beacon Equity Research has not been compensated by any of the companies covered in this release. It is the policy of Beacon Research and its affiliates to sell any stock received for services, which may cause the stock price to become depressed. Our affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. We may sell shares for less than the target price given in this opinion, or at any time following the issuance of this announcement. We will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Beacon Research and its owners undertake no obligation to update such statements.
